Single-shot COVID-19 vaccine generates robust immune responses against variants.

A Wyss Institute-led collaboration has used the institute’s organ-on-a-chip technology to identify the antimalarial drug amodiaquine as a potent inhibitor of infection with SARS-CoV-2, the virus that causes COVID-19.

Though the so-far-successful U.S. vaccination drive is likely to deliver an approximation of normal life by year’s end, Anthony Fauci and a panel of heath care experts cautioned that the global battle against COVID-19 is far from won.

As the pandemic reaches what experts hope will be its latter stages, the health care system is seeing more “long COVID” patients, those whose often mild initial illness has been followed up by months of severe, sometimes debilitating symptoms. The Gazette spoke with an expert to find out more.

FDA approval of two over-the-counter rapid antigen tests promises to transform the testing landscape around COVID-19, lowering cost and giving the certainty of knowing when you’re infected to the individual, a Harvard epidemiologist said.

Pregnant women show robust immune response to COVID vaccines, pass antibodies to newborns.

A $25 billion investment in global vaccines would bring a five-to-one economic return and save many lives, according to Rebecca Weintraub, an HMS global health expert.

A new trial seeks to test whether cheap rapid tests given three times a week can keep the workplace safe despite the coronavirus pandemic.

Harvard researchers looked at Katrina’s impact on children and how the lessons learned there could be applied to the COVID pandemic.

Can the current crop of vaccines get us to herd immunity even if variants become widespread? A Harvard immunologist says yes.